Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Cash Flow (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Net Cash Flow for 8 consecutive years, with -$107.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 909.29% to -$107.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.3 million, a 119.16% increase, with the full-year FY2024 number at -$34.2 million, down 243.36% from a year prior.
  • Net Cash Flow was -$107.0 million for Q3 2025 at Whitehawk Therapeutics, down from -$82.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $198.8 million in Q1 2025 to a low of -$107.0 million in Q3 2025.
  • A 5-year average of $1.8 million and a median of -$5.9 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 1753.98% in 2024, then skyrocketed 2283.08% in 2025.
  • Whitehawk Therapeutics' Net Cash Flow stood at -$12.4 million in 2021, then tumbled by 673.42% to -$95.8 million in 2022, then skyrocketed by 93.83% to -$5.9 million in 2023, then surged by 68.44% to -$1.9 million in 2024, then tumbled by 5631.39% to -$107.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Net Cash Flow are -$107.0 million (Q3 2025), -$82.6 million (Q2 2025), and $198.8 million (Q1 2025).